Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/10682
Título : Orally bioavailable and effective Buparvaquone lipid-based nanomedicines for visceral leishmaniasis / Lindsay Smith ... [et al.].
Autor : Smith, Lindsay.
Serrano López, Dolores Remedios.
Mauger, Marion.
Bolas Fernández, Francisco.
Dea Ayuela, María Auxiliadora.
Lalatsa, Katerina.
Materias: Leishmaniasis - Farmacoterapia.Leishmaniasis - Chemotherapy.Medicamentos - Administración.Drugs - Administration.Communicable diseases - Treatment.Enfermedades parasitarias - Tratamiento.Parasitic diseases - Treatment.Enfermedades infecciosas - Tratamiento.Buparvaquone.
Fecha de publicación : 15-may-2018
Editorial : American Chemical Society.
Citación : Smith, L., Serrano, DR., Mauger, M., Bolás-Fernández, F., Dea-Ayuela, MA. & Lalatsa, A. (2018). Orally bioavailable and effective Buparvaquone lipid-based nanomedicines for visceral leishmaniasis. Molecular Pharmaceutics, vol. 15, n. 7 (15 may), pp. 2570-2583. DOI: https://doi.org/10.1021/acs.molpharmaceut.8b00097
Resumen : Nano-enabled lipid based drug delivery systems offer a platform to overcome challenges encountered with current failed leads in the treatment of parasitic and infectious diseases. When prepared with FDA or EMA approved excipients, they can be readily translated without the need for further toxicological studies, while they remain affordable and amenable to scale-up. Buparvaquone (BPQ), a hydroxynapthoquinone with in vitro activity in the nanomolar range, failed to clinically translate as a viable treatment for visceral leishmaniasis due to its poor oral bioavailability limited by its poor aqueous solubility (BCS Class II drug). Here we describe a self-nanoemulsifying system (SNEDDS) with high loading and thermal stability up to 6 months in tropical conditions able to enhance the solubilisation capacity of BPQ in gastrointestinal media as demonstrated by flow-through cell and dynamic in vitro lipolysis studies. BPQ SNEDDS demonstrated an enhanced oral bioavailbility compared to aqueous BPQ dispersions (probe – sonicated) resulting in an increased plasma AUC0-24 by 55% that is four fold higher than any previous reported values for BPQ formulations. BPQ SNEDDS can be adsorbed on low molecular glycol chitosan polymers forming solid dispersions that when compressed into tablets allow the complete dissolution of BPQ in gastrointestinal media. BPQ SNEDDS and BPQ solid SNEDDS demonstrated potent in vitro efficacy in the nanomolar range (<37 nM) and were able to near completely inhibit parasite replication in the spleen and 48 ± 48 and 56 ± 23% inhibition of the parasite replication in the liver respectively compared to oral miltefosine after daily administration over 10 days. The proposed platform technology can be used to elicit a range of cost-effective and orally bioavailable non-invasive formulations for a range of antiparasitic and infectious disease drugs that are needed for closing the global health innovation gap.
Descripción : Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.8b00097
This is the pre-peer reviewed version of the following article: Smith, L., Serrano, DR., Mauger, M., Bolás-Fernández, F., Dea-Ayuela, MA. & Lalatsa, A. (2018). Orally bioavailable and effective Buparvaquone lipid-based nanomedicines for visceral leishmaniasis. Molecular Pharmaceutics, vol. 15, n. 7 (15 may), pp. 2570-2583, which has been published in final form at https://doi.org/10.1021/acs.molpharmaceut.8b00097.
Este es el pre-print del siguiente artículo: Smith, L., Serrano, DR., Mauger, M., Bolás-Fernández, F., Dea-Ayuela, MA. & Lalatsa, A. (2018). Orally bioavailable and effective Buparvaquone lipid-based nanomedicines for visceral leishmaniasis. Molecular Pharmaceutics, vol. 15, n. 7 (15 may), pp. 2570-2583, que se ha publicado de forma definitiva en https://doi.org/10.1021/acs.molpharmaceut.8b00097.
URI : http://hdl.handle.net/10637/10682
Derechos: http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
ISSN : 1543-8384
1543-8392 (Electrónico)
Aparece en las colecciones: Dpto. Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.